Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10768544 | 1.00 | ELANE (0.48) | ELANEHTR2AALDH1A1MAPTHPGD | |
| SCHEMBL10675931 | 1.00 | ELANE (0.48) | ELANEHTR2AALDH1A1MAPTHPGD | |
| SCHEMBL14875217 | 1.00 | ELANE (0.48) | ELANEHTR2AALDH1A1MAPTHPGD | |
| SCHEMBL9039878 | 1.00 | ELANE (0.48) | ELANEHTR2AALDH1A1MAPTHPGD | |
| SCHEMBL18036888 | 1.00 | ELANE (0.48) | ELANEHTR2AALDH1A1MAPTHPGD | |
| SCHEMBL10767245 | 1.00 | ELANE (0.48) | ELANEHTR2AALDH1A1MAPTHPGD | |
| SCHEMBL6893609 | 1.00 | ELANE (0.48) | ELANEHTR2AALDH1A1MAPTHPGD | |
| SCHEMBL10758551 | 1.00 | ELANE (0.48) | ELANEHTR2AALDH1A1MAPTHPGD | |
| SCHEMBL10670342 | 0.91 | HTR2A (0.43) | ELANEHTR2AALDH1A1MAPTHPGD | |
| SCHEMBL10676045 | 0.91 | HTR2A (0.43) | ELANEHTR2AALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095210-A1 | PROCESS FOR THE PREPARATION OF BETA-LACTAM ANTIBIOTIC | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2012-04-19 | — | — | US | disclosed |
| US-8148520-B2 | Process for the preparation of beta-lactam antibiotic meropenem trihydrate | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2012-04-03 | — | — | US | disclosed |
| US-8093378-B2 | Crystallization method for intermediates of carbapenem antibiotics | KANEKA CORPORATION (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8093378-B2 | Crystallization method for intermediates of carbapenem antibiotics | KANEKA CORPORATION (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20090118496-A1 | Crystallization Method for Intermediates of Carbapenem Antibiotics | KANEKA CORPORATION (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118496-A1 | Crystallization Method for Intermediates of Carbapenem Antibiotics | KANEKA CORPORATION (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-0333175-A1 | 3-Pyrrolidinylthio-1-azabicyclo (3.2.0)hept-2-ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118496-A1 | Crystallization Method for Intermediates of Carbapenem Antibiotics | OTUB1, PYCARD, OTUD7B | ELANE 3442/4885HTR2A 1861/4885ALDH1A1 2860/4885 |
| US-20120095210-A1 | PROCESS FOR THE PREPARATION OF BETA-LACTAM ANTIBIOTIC | MGAM, BPGM, MPDU1 | ELANE 2479/4885HTR2A 4722/4885ALDH1A1 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.